S3 treatment activated AMPK and repressed ACC1 and mTOR pathways in a dose-dependent manner in multiple PCa cell lines, as revealed by increased levels of phospho-AMPK (pAMPK) and phospho-ACC1 (pACC1) and decreased levels of phospho-S6K (pS6K)/phospho-S6 (pS6) (Figure 5B,C). This evidence concerns the gene RPS6KB1 and posterior cortical atrophy.